BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce bacteriocin activity. It operates in the following geographical areas: Asia Pacific, Europe Middle East and Africa (EMEA), and North America. The company was founded by John R. Tagg in 2000 and is headquartered in Dunedin, New Zealand.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company